(Date:11/30/2009)...swire-USNewswire/ -- The Michael J. Fox Foundation...1.5 million in total awards to six research teams ...herapies for Parkinson,s disease. The funding was ...ery for Parkinson,s Disease program, made possibl...LN ), a neuroscience-based biotechnology company. ...
(Date:11/30/2009)...30 Biopharmaceutical company Kiadi...ave been enrolled in its,multinational registratio...ned to show reduction in transplant related mortal...tem cell transplantation with a mismatched,(haplo-... for an allogeneic,stem cell transplantation but w...
(Date:11/30/2009)... Novavax, Inc. (Nasdaq: ... in the Phase II clinical study of its trivalent s...VLP vaccine candidate in healthy adults 60 years o...ouble-blind, active-controlled study is comparing ... different doses (15 mcg and 60 mcg) of Novavax,s ...
(Date:11/30/2009)...RNewswire-FirstCall/ -- Cell Therapeutics, Inc. (C...s new class of platinum-based anti-tumor compounds...nti-tumor potency and activity compared to current...he ability to overcome cisplatin-resistance in can...aper titled "Novel Bis-platinum Complexes Endowed ...
Breaking Biology Technology:The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3... (Nasdaq: INSM ), a developer of follow-on biolo... that on Monday, March 23, 2009, NASDAQ issued a n...s requiring a minimum $1 closing bid price and tho...cly held shares (MVPHS). The suspension will rema...e original rules will be reinstated on Monday, Jul...
...all/ - Spectral Diagnostics Inc. (TSX:SDI), a comp...s, today announced that the 29th International Sym... Brussels, Belgium from March 24-27, 2009 will fea...e of Endotoxin", that will include presentations f...esentations will include topics such as defining t...
...all/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX...on of patient enrolment in its U.K. clinical trial...s administration of REOLYSIN(R) in combination wit...d cancers including breast, and head and neck. The... The Royal Marsden NHS Foundation Trust and The In...
Other Biology Technology:Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule 2Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3Pyrex brand Fernback baffled culture flask from Sigma-Aldrich
... simple and efficient means for isolation of apopt...netic beads (MagBeads). Annexin V is a Ca2+-depend...y for phosphatidylseri The Apoptotic Cell Isolati...solation of apoptotic cells or removal of dead cel...
Xylene Cyanole FF from Sigma-Aldrich
...igned to be a solid, heavy-duty durable orbital sh...ng and vortexing in nature. The VSOS-4 Orbital ...uniform orbital shaking motion (19mm circular) for...ell/tissue culture, hybridization, staining and de...
Biology Products: